Getting investigational medicinal products to the patient: three routes

In clinical trials, IMPs are traditionally shipped from suppliers to clinical centers and administered by investigators, or collected from the site and taken home. Decentralized and hybrid models, which are fast becoming the preferred approach from patients and sponsors, are changing this dynamic as they bring a new alternative to the common routes for getting IMPs to patients.

Here are three routes for getting IMPs to patients to support a successful trial.